Summary
Fifteen patients with measurable metastatic transitional cell bladder cancer were treated with VP 16-213 100 mg/m2 IV daily for 4 days, repeated every 3 weeks. There were no complete or partial (greater than 50% reduction in area, maintained for 6 weeks) responses. Two patients showed transient reduction by 50% in the area of measurable lesions, and a further five patients showed brief stabilisation of previously progressive disease. The treatment was well tolerated. In two patients, total WBC at the nadir fell below 1.0×109/l but without complications from infection.
We conclude that VP 16-213 is inactive in metastatic transitional cell urothelial cancer.
This is a preview of subscription content, log in via an institution to check access.
References
Arnold AM (1979) Podophyllotoxin derivative VP 16-213. Cancer Chemother Pharmacol 3: 71
Creaven PJ, Newman SJ, Selawry OS, Cohen MH, Primack A (1974) Phase I clinical trial of weekly administration of 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemother Rep 58: 901
European Organization for Research on the Treatment of Cancer: Clinical Screening Group (1973) Epipodophyllotoxin VP 16-213 in treatment of acute leukaemias, haematosarcomas, and solid tumours. Br Med J III: 199
Falkson G, van Dyk JJ, van Eden EB, van der Merwe AM, van den Bergh JA, Falkson HC (1975) A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-d-ethylidene glucoside (NSC 141540) VP 16-213. Cancer 35: 1141
Fitzharris BM, Kaye SB, Saverymuttu S, Newlands ES, Barrett A, Peckham MJ, McElwain TJ (1980) VP 16-213 as a single agent in advanced testicular tumours. Eur J Cancer 16: 1193
Hall RR, Bloom HJG, Freeman JE, Nawrocki A, Wallace DM (1974) Methotrexate treatment for advanced bladder cancer. Br J Urol 46: 431
Jungi WF (1982) Etoposide single-agent chemotherapy for solid tumors. Cancer Treat Rev 9: 31
Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, Silver RT, Weiss RB, Cuttner J, Falkson G, Kung F, Bergevin PR, Holland JF (1980) Clinical trial of VP 16-213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease. Cancer 45: 232
Oliver RTD, Newlands ES, Wiltshaw E, Malpas JS (1981) A phase 2 study of cis-platinum in patients with recurrent bladder carcinoma. Br J Urol 53: 444
Oliver RTD, England HR, Risdon RA, Blandy JP (1983) Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma. J Urol (in press)
Panduro J, Hansen M, Hansen HH (1981) Oral VP 16-213 in transitional cell carcinoma of the bladder: a phase II study. Cancer Treat Rep 65: 703
Schmoll H (1982) Review of etoposide single-agent activity. Cancer Treat Rev 9: 21
Turner AG, Hendry WF, Williams GB, Bloom HJG (1977) The treatment of advanced bladder cancer with methotrexate. Br J Urol 49: 673
Turner AG, Durrant KR, Malpas JS (1979) A trial of bleomycin versus adriamycin in advanced carcinoma of the bladder. Br J Urol 51: 121
Yagoda A (1980) Chemotherapy of metastatic bladder cancer. Cancer 45: 1879
Author information
Authors and Affiliations
Additional information
for the Chemotherapy Subcommittee of the Co-operative Urological Cancer Group of England, Royal Marsden Hospital, Fulham Road, London, SW3
Members of the Subcommittee: Prof. J. S. Malpas, Dr E. D. Newlands, Dr R. T. D. Oliver, Dr B. A. J. Ponder
Rights and permissions
About this article
Cite this article
Ponder, B.A.J., Oliver, R.T.D. Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer. Cancer Chemother. Pharmacol. 12, 64–65 (1984). https://doi.org/10.1007/BF00255913
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255913